<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04233801</url>
  </required_header>
  <id_info>
    <org_study_id>1245-0191</org_study_id>
    <nct_id>NCT04233801</nct_id>
  </id_info>
  <brief_title>A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin</brief_title>
  <official_title>A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Empagliflozin (10 mg and 25 mg) Administered Orally Once Daily in Combination With Insulin With or Without up to Two Oral Anti-diabetic Agents for 24 Weeks in Chinese Type 2 Diabetic Patients With Insufficient Glycemic Control.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study in Chinese adults with type 2 diabetes. The study is open to people who take&#xD;
      insulin but still have too high blood sugar levels. Participants may additionally be taking&#xD;
      up to 2 other medicines for their diabetes. The purpose of this study is to find out whether&#xD;
      empagliflozin taken together with insulin helps people with type 2 diabetes to better control&#xD;
      their blood sugar.&#xD;
&#xD;
      The participants are in the study for about 7 months. During this time, they visit the study&#xD;
      site about 8 times, 1 additional visit may be either a visit to the study site or a phone&#xD;
      call. At the start of the study, participants are put into 3 groups by chance. Participants&#xD;
      get either 10 mg empagliflozin tablets, or 25 mg empagliflozin tablets, or placebo tablets&#xD;
      once a day. Placebo tablets look like empagliflozin tablets but do not contain any medicine.&#xD;
&#xD;
      The doctors regularly take blood samples from the participants. The changes in blood sugar&#xD;
      levels are compared between the groups. The doctors also check the general health of the&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">March 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 21, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in glycosylated haemoglobin A1c (HbA1c)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with HbA1c&lt;7.0%</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure (SBP)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic blood pressure (DBP)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 2-hour Post-prandial Glucose (PPG)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of hypoglycemic events</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adjudicated diabetic ketoacidosis (DKA) events</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Empagliflozin low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Empagliflozin</description>
    <arm_group_label>Empagliflozin high dose</arm_group_label>
    <arm_group_label>Empagliflozin low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years and ≤75 years old at Visit 1;&#xD;
&#xD;
          -  Chinese patient with diagnosis of Type 2 diabetes prior to Visit 1;&#xD;
&#xD;
          -  A stable treatment with premixed Insulin (≥ 20IU/day) or basal insulin (≥ 16 IU/day)&#xD;
             for at least 12 weeks prior to enrolment with or without up to two OADs&#xD;
&#xD;
               -  With maximum insulin dose of ≤ 1 unit/kg/day. Acceptable basal insulins should&#xD;
                  have duration of action up to 24 h such as insulin Degludec, insulin glargin,&#xD;
                  insulin detemir or NPH (neutral protamine hagedorn) insulin; Acceptable pre-mixed&#xD;
                  insulins could be once or twice daily posology only. The total insulin dose&#xD;
                  should not be changed by more than 20% of the baseline value within the 12 weeks&#xD;
                  prior to randomisation (Visit 3). Both human insulin &amp; insulin analogue are&#xD;
                  acceptable;&#xD;
&#xD;
               -  If the patient is taking OADs, regimen has to be unchanged for at least 12 weeks&#xD;
                  prior to randomization (Visit 3);&#xD;
&#xD;
               -  If the patient is taking metformin, stable dose (at least 1500 mg daily or&#xD;
                  maximum tolerated dose) must be maintained for at least 12 weeks without dose&#xD;
                  adjustments prior to randomization (Visit 3);&#xD;
&#xD;
          -  HbA1c ≥7.5% and ≤11.0% at Visit 1;&#xD;
&#xD;
          -  Fasting C-peptide: &gt;0.5 ng/mL (&gt;166pmol/L) at Visit 1；&#xD;
&#xD;
          -  18.5 kg/m2 ≤ BMI ≤ 45 kg/m2 at Visit 1;&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with ICH-GCP and local&#xD;
             legislation prior to admission to the trial;&#xD;
&#xD;
          -  Male or female patients. Women of childbearing potential (WOCBP) must be ready and&#xD;
             able to use highly effective methods of birth control per ICH M3 (R2) that result in a&#xD;
             low failure rate of less than 1% per year when used consistently and correctly. A list&#xD;
             of contraception methods meeting these criteria is provided in the patient&#xD;
             information.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Type 1 diabetes;&#xD;
&#xD;
          -  Patients receiving MDI insulin or insulin pump treatment;&#xD;
&#xD;
          -  eGFR &lt;45ml/min/1.73m2 calculated based on MDRD formula;&#xD;
&#xD;
          -  Uncontrolled hyperglycemia [glucose level &gt;13. 9 mmol/l after an overnight fast during&#xD;
             placebo run-in];&#xD;
&#xD;
          -  Severe hypoglycemia episode (event requiring the assistance of another person to&#xD;
             actively administer carbohydrate, glucagon or other resuscitative actions) within 6&#xD;
             months prior to Visit 1;&#xD;
&#xD;
          -  History of diabetic ketoacidosis or hyperosmolar non-ketotic coma. Myocardial&#xD;
             infarction, stroke or transient ischaemic attack within 3 months prior to Visit 1;&#xD;
&#xD;
          -  Bariatric surgery;&#xD;
&#xD;
          -  Further criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Pinggu Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The third xiangya hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chongqing Three Gorges Central Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital, Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Third Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Hangzhou Normal University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital to Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The affiliated hospital of medicalcollege qingdao university</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospital of Putuo District, Shanghai</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Fifth People's Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongren hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzhou Municipal Hospital</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Chu Hisen-I Memorial Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

